<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Unipolar depression in adults: Treatment with antidepressant combinations
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Unipolar depression in adults: Treatment with antidepressant combinations
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Unipolar depression in adults: Treatment with antidepressant combinations
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            A John Rush, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter P Roy-Byrne, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Solomon, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H7346865">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antidepressant combinations are generally used for unipolar major depression (major depressive disorder) that is resistant to treatment with antidepressant monotherapy. Add-on pharmacotherapy is often necessary because initial treatment with a single antidepressant leads to remission in only 30 to 50 percent of patients [
         <a href="#rid1">
          1-3
         </a>
         ]. Options for adjunctive pharmacotherapy include a second antidepressant, as well as second-generation antipsychotics,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , and triiodothyronine. Adjunctive psychotherapy is also an option.
        </p>
        <p>
         Combining two antidepressants for treatment resistant depression is common [
         <a href="#rid4">
          4
         </a>
         ]. As an example, retrospective studies of patients treated for depression with a single antidepressant (insurance claims database n &gt;134,000; registry database n &gt;240,000) found that a second antidepressant was added in approximately 10 percent of patients [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p>
         This topic reviews the indications and efficacy of combining antidepressants for patients with unipolar, nonpsychotic major depression. Choosing a drug regimen for major depression and using a second antidepressant as a hypnotic are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">
          "Unipolar depression in adults: Choosing treatment for resistant depression"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">
          "Unipolar major depression in adults: Choosing initial treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/97868.html" rel="external">
          "Pharmacotherapy for insomnia in adults", section on 'Antidepressants'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18277385">
         <span class="h1">
          INDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Indications for antidepressant combinations include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unipolar major depression that does not respond to multiple courses of treatment with antidepressant monotherapy as well as an antidepressant plus adjunctive pharmacotherapy (eg, antidepressant plus a second-generation antipsychotic,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , or triiodothyronine). (See
         <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">
          "Unipolar depression in adults: Choosing treatment for resistant depression", section on 'Choosing a drug'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unipolar major depression characterized by prominent insomnia – An antidepressant (eg, SSRI or
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         ) can be augmented with another antidepressant such as low dose
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          doxepin
         </a>
         or
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/97868.html" rel="external">
          "Pharmacotherapy for insomnia in adults", section on 'Antidepressants'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         We suggest that clinicians generally avoid combining antidepressants as initial treatment for unipolar major depression, because the evidence suggests that this approach does not provide any advantage over antidepressant monotherapy (see
         <a class="local">
          'Initial treatment of depression'
         </a>
         below). However, it is reasonable to initiate treatment with two antidepressants in patients who suffer a recurrent episode and who previously responded to antidepressant combinations after not responding to other antidepressant regimens.
        </p>
        <p class="headingAnchor" id="H78563143">
         <span class="h1">
          PRESCRIBING ANTIDEPRESSANT COMBINATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H18277698">
         <span class="h2">
          General principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         No evidence-based guidelines have been established for combining antidepressants in patients with unipolar major depression. Nevertheless, when clinicians combine antidepressants, we suggest using [
         <a href="#rid7">
          7,8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs that do not pose greater safety or tolerability risks than monotherapy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs with distinct pharmacodynamic effects (mechanisms of action)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs with a limited range of pharmacodynamic effects
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs that do not have opposing mechanisms of action
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs with few or no pharmacokinetic interactions
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs with simple metabolisms
        </p>
        <p>
        </p>
        <p>
         In addition, the dose of antidepressants used in combination treatments should generally follow accepted dosing guidelines used in monotherapy for selected agents.
        </p>
        <p class="headingAnchor" id="H18277417">
         <span class="h2">
          Drug-drug interactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain antidepressant combinations should be avoided, such as a monoamine oxidase inhibitor (MAOI) plus a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor, which can cause the serotonin syndrome or a hypertensive crisis [
         <a href="#rid7">
          7
         </a>
         ]. The combination of a tricyclic plus an MAOI is generally avoided as well due to the same safety concerns, and study results that show no benefit with this combination [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1715.html" rel="external">
          "Monoamine oxidase inhibitors (MAOIs): Pharmacology, administration, safety, and side effects"
         </a>
         .)
        </p>
        <p>
         Other antidepressant combinations that are reasonable may nevertheless cause problems that may be avoided by therapeutic drug monitoring. As an example, in a case series of three patients with unipolar major depression who did not respond to
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         monotherapy,
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         was added [
         <a href="#rid10">
          10
         </a>
         ]. Bupropion increased venlafaxine levels, which in one patient led to agitation, headache, and insomnia; these adverse effects resolved with discontinuation of bupropion. Venlafaxine is a substrate of cytochrome P450 enzyme 2D6, whereas bupropion inhibits the enzyme.
        </p>
        <p>
         Specific interactions between antidepressants may be determined using the
         <a class="external" href="/drug-interactions">
          Lexicomp drug interactions
         </a>
         tool (Lexi-Interact Online) included in UpToDate.
        </p>
        <p class="headingAnchor" id="H78563111">
         <span class="h2">
          Measurement based care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Outcomes for patients with major depression may be enhanced with measurement based care, which involves monitoring progress by serially measuring severity of symptoms with a standardized scale and using these measurements to adjust the treatment plan as necessary. Psychosocial functioning, side effects, and adherence can also be quantified. (See
         <a class="medical medical_review" href="/z/d/html/14860.html" rel="external">
          "Using scales to monitor symptoms and treat depression (measurement based care)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18277424">
         <span class="h1">
          TREATMENT RESISTANT DEPRESSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The term “treatment resistant depression” typically refers to major depressive episodes that do not respond satisfactorily after one or two trials of antidepressant monotherapy; however, the definition has not been standardized. Many patients with treatment resistant depression are prescribed a second antidepressant as add-on therapy. The sections below discuss the unclear benefit of this practice.
        </p>
        <p>
         Additional information about treatment resistant depression in adults is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/87498.html" rel="external">
          "Unipolar treatment-resistant depression in adults: Epidemiology, risk factors, assessment, and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">
          "Unipolar depression in adults: Choosing treatment for resistant depression"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1163204576">
         <span class="h2">
          Unclear benefit from antidepressant combinations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with unipolar, nonpsychotic major depression who do not respond to initial treatment with antidepressant monotherapy frequently receive add-on therapy with a second antidepressant from a different class (often referred to as combination therapy) [
         <a href="#rid11">
          11
         </a>
         ]. Combination therapy with a second antidepressant is distinguished from add-on therapy with a medication that is not an antidepressant monotherapy, such as a second-generation antipsychotic or
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         .
        </p>
        <p>
         While some randomized trials support combination therapy with two antidepressants, others do not. As an example, a systematic review identified five randomized trials in patients with treatment resistant depression (total n = 483) that compared an antidepressant plus a second antidepressant with an antidepressant plus placebo, and found that combination treatment was often not beneficial [
         <a href="#rid12">
          12
         </a>
         ]. In three trials (total n = 387), response was comparable for patients who received either combination treatment or monotherapy, whereas the other two trials (total n = 96) found that response was superior with combination therapy. In the largest trial (n = 293), at least one adverse effect occurred in more patients who received the combination than in those who received monotherapy (77 versus 51 percent) [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H254491846">
         <span class="h3">
          Evidence that antidepressant combinations are not beneficial
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with treatment resistant depression, multiple placebo-controlled trials indicate that antidepressant combinations are not beneficial:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A network meta-analysis of 48 randomized trials (n &gt;6000 depressed patients) evaluated the efficacy of augmentation agents, including adjunctive
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         , by using results from direct comparisons between the drugs, as well as indirectly comparing drugs through their relative effect with a common comparator (typically placebo) [
         <a href="#rid14">
          14
         </a>
         ]. Remission with adjunctive bupropion and adjunctive placebo was comparable, as was response (reduction of baseline symptoms ≥50 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A subsequent, six-week randomized trial compared
         <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">
          duloxetine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         with duloxetine plus placebo in 46 patients with treatment resistant depression, and found that response was comparable with adjunctive bupropion or placebo (26 and 22 percent of patients) [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another trial enrolled patients (n = 480) who had not responded to at least six weeks of antidepressant monotherapy and randomly assigned them to add-on treatment with
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         (30 mg/day) or placebo for 12 weeks; patients receiving psychotherapy at baseline were allowed to continue it [
         <a href="#rid16">
          16
         </a>
         ]. Remission was comparable with adjunctive mirtazapine and placebo (29 and 24 percent of patients); among patients receiving mirtazapine or placebo, adverse effects occurred in 50 and 30 percent.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2897153235">
         <span class="h3">
          Evidence that antidepressant combinations are beneficial
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who do not respond to initial antidepressant monotherapy, some randomized trials indicate that combining two antidepressants can be useful [
         <a href="#rid17">
          17
         </a>
         ]. As an example:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two open-label 14-week randomized trials from the Sequenced Treatment Alternatives to Relieve Depression study compared the benefit of two antidepressants with an active control condition:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         One trial compared
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         sustained release (mean dose 268 mg per day) plus
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         with
         <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">
          buspirone
         </a>
         (mean dose 41 mg per day) plus citalopram as next step treatment in 565 patients with major depression who did not respond to citalopram alone [
         <a href="#rid18">
          18
         </a>
         ]. Reduction of symptoms was greater with bupropion plus citalopram; in addition, discontinuation of treatment due to side effects occurred in fewer patients with bupropion plus citalopram than buspirone plus citalopram (13 versus 21 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The second trial compared
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         (mean dose 36 mg per day) plus
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         extended release (mean dose 210 mg per day) with
         <a class="drug drug_general" data-topicid="10012" href="/z/d/drug information/10012.html" rel="external">
          tranylcypromine
         </a>
         (mean dose 37 mg per day) alone in 109 patients who had not responded to three prior prospective courses of treatment [
         <a href="#rid19">
          19
         </a>
         ]. Remission with tranylcypromine and with the combination was comparable (7 and 14 percent); however, symptom reduction was superior with mirtazapine plus venlafaxine. In addition, discontinuation of treatment due to side effects occurred in fewer patients who received the combination than tranylcypromine monotherapy (22 versus 41 percent). The average dose of tranylcypromine (37 mg per day) was such that few patients received a vigorous course of MAOI therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In addition, a four-week randomized trial compared
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         sustained release with placebo as add-on treatment in 60 patients who had not responded adequately to four weeks of monotherapy with a selective serotonin reuptake inhibitor; only patients were blind to treatment [
         <a href="#rid20">
          20
         </a>
         ]. Remission occurred in more patients who received adjunctive bupropion than placebo (60 versus 23 percent).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18277431">
         <span class="h1">
          INITIAL TREATMENT OF DEPRESSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prescribing two antidepressants at the onset of treatment for unipolar nonpsychotic major depression does not appear to provide any advantage over antidepressant monotherapy. Although some randomized trials have found that antidepressant combinations are more efficacious than monotherapy, larger trials found no benefit in using antidepressant combinations.
        </p>
        <p>
         Evidence that suggests antidepressant combinations are efficacious as initial treatment for unipolar major depression includes a meta-analysis of four randomized trials (250 patients) that initiated treatment with an antidepressant combination or antidepressant monotherapy [
         <a href="#rid21">
          21
         </a>
         ]. Remission was nearly three times more likely with combination treatment (relative risk 2.7, 95% CI 1.7-4.4), and discontinuation of treatment due to adverse effects was comparable for the two groups. Medication combinations included:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          Mirtazapine
         </a>
         plus selective serotonin reuptake inhibitors (
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         or
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          Mirtazapine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          Mirtazapine
         </a>
         plus
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Selective serotonin reuptake inhibitors (
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         or
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         ) plus tricyclics (
         <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">
          desipramine
         </a>
         or
         <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">
          nortriptyline
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         However, larger randomized trials (conducted after the meta-analysis) found that for initial treatment of unipolar major depression, antidepressant combinations and antidepressant monotherapy were comparable:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 12-week trial compared
         <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">
          escitalopram
         </a>
         plus placebo, escitalopram plus sustained release
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         , and
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         plus extended release
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         in 665 patients with unipolar major depression; only patients were blind to treatment allocation [
         <a href="#rid22">
          22
         </a>
         ]. Remission occurred in approximately 39 percent of the patients in each group, and tolerability was poorer with mirtazapine plus venlafaxine than escitalopram plus placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another 12-week trial compared
         <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">
          escitalopram
         </a>
         plus
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         extended release, escitalopram alone, and bupropion alone in 245 patients with unipolar major depression; remission was comparable for the three groups [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Melancholic features were present in most patients who participated in trials that found antidepressant combinations were superior to antidepressant monotherapy [
         <a href="#rid24">
          24,25
         </a>
         ]. By contrast, melancholic features were present in only a minority of patients in trials that did not find any benefit in using antidepressant combinations [
         <a href="#rid22">
          22,23
         </a>
         ]. The presence of melancholic features may indicate a greater severity of illness that is more amenable to aggressive treatment at the outset [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
         In addition, different antidepressant medication combinations may differ in efficacy. The meta-analysis described above in this section focused largely on combinations with
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         [
         <a href="#rid21">
          21
         </a>
         ], while the two large randomized controlled trials both evaluated selective serotonin reuptake inhibitor plus
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p>
         Additional information about the initial treatment of unipolar major depression is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/90153.html" rel="external">
          "Unipolar depression in adults and initial treatment: General principles and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">
          "Unipolar major depression in adults: Choosing initial treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90154.html" rel="external">
          "Unipolar depression in adult primary care patients and general medical illness: Evidence for the efficacy of initial treatments"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90155.html" rel="external">
          "Unipolar depression in adults: Investigational and nonstandard treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3165730651">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116503.html" rel="external">
          "Society guideline links: Depressive disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H78562923">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Indications for combining two antidepressants include unipolar major depression that does not respond to multiple courses of treatment with antidepressant monotherapy as well as an antidepressant plus adjunctive pharmacotherapy (eg, antidepressant plus a second-generation antipsychotic or
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ). (See
         <a class="local">
          'Indications'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">
          "Unipolar depression in adults: Choosing treatment for resistant depression", section on 'Choosing a drug'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When prescribing antidepressant combinations, it is preferable to use antidepressants with distinct mechanisms of action. Certain antidepressant combinations should be avoided, such as a monoamine oxidase inhibitor plus a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor. (See
         <a class="local">
          'Prescribing antidepressant combinations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with unipolar, nonpsychotic major depression who do not respond to initial treatment with antidepressant monotherapy often receive add-on therapy with a second antidepressant; however, it is not clear that this practice is beneficial, due to inconsistent results from randomized trials. (See
         <a class="local">
          'Treatment resistant depression'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prescribing two antidepressants at the onset of treatment for unipolar nonpsychotic major depression does not appear to provide any advantage over antidepressant monotherapy. (See
         <a class="local">
          'Initial treatment of depression'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1120991557">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Madhukar Trivedi, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005; 66:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thase ME, Nierenberg AA, Vrijland P, et al. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol 2010; 25:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gersing KR, Sheehan JJ, Burchett B, et al. Use of augmentation agents for treating depression: analysis of a psychiatric electronic medical record data set. Psychiatr Serv 2014; 65:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milea D, Guelfucci F, Bent-Ennakhil N, et al. Antidepressant monotherapy: A claims database analysis of treatment changes and treatment duration. Clin Ther 2010; 32:2057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valenstein M, McCarthy JF, Austin KL, et al. What happened to lithium? Antidepressant augmentation in clinical settings. Am J Psychiatry 2006; 163:1219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Preskorn SH. Treatment options for the patient who does not respond well to initial antidepressant therapy. J Psychiatr Pract 2009; 15:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Preskorn SH, Lacey RL. Polypharmacy: when is it rational? J Psychiatr Pract 2007; 13:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young JP, Lader MH, Hughes WC. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. Br Med J 1979; 2:1315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paslakis G, Gilles M, Deuschle M. Clinically relevant pharmacokinetic interaction between venlafaxine and bupropion: a case series. J Clin Psychopharmacol 2010; 30:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thase ME. Antidepressant combinations: cutting edge psychopharmacology or passing fad? Curr Psychiatry Rep 2013; 15:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopes Rocha F, Fuzikawa C, Riera R, et al. Antidepressant combination for major depression in incomplete responders--a systematic review. J Affect Disord 2013; 144:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl) 2002; 161:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry 2015; 76:e487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fornaro M, Martino M, Mattei C, et al. Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol 2014; 24:1269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kessler DS, MacNeill SJ, Tallon D, et al. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). BMJ 2018; 363:k4218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry 2016; 61:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354:1243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006; 163:1531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gulrez G, Badyal DK, Deswal RS, Sharma A. Bupropion as an augmenting agent in patients of depression with partial response. Basic Clin Pharmacol Toxicol 2012; 110:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rocha FL, Fuzikawa C, Riera R, Hara C. Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis. J Clin Psychopharmacol 2012; 32:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011; 168:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart JW, McGrath PJ, Blondeau C, et al. Combination antidepressant therapy for major depressive disorder: speed and probability of remission. J Psychiatr Res 2014; 52:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blier P, Gobbi G, Turcotte JE, et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009; 19:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010; 167:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coryell W. The search for improved antidepressant strategies: is bigger better? Am J Psychiatry 2011; 168:664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parker G, Fink M, Shorter E, et al. Issues for DSM-5: whither melancholia? The case for its classification as a distinct mood disorder. Am J Psychiatry 2010; 167:745.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 14671 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16390886" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16086611" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20531012" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24932958" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Use of augmentation agents for treating depression: analysis of a psychiatric electronic medical record data set.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21118742" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Antidepressant monotherapy: A claims database analysis of treatment changes and treatment duration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16816227" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : What happened to lithium? Antidepressant augmentation in clinical settings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19461393" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Treatment options for the patient who does not respond well to initial antidepressant therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17414685" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Polypharmacy: when is it rational?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/391342" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20631572" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clinically relevant pharmacokinetic interaction between venlafaxine and bupropion: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24052267" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Antidepressant combinations: cutting edge psychopharmacology or passing fad?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22835845" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Antidepressant combination for major depression in incomplete responders--a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11981594" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25919841" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24842649" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30381374" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27486148" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16554526" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Medication augmentation after the failure of SSRIs for depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16946177" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21895979" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Bupropion as an augmenting agent in patients of depression with partial response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22367652" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21536692" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24485847" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Combination antidepressant therapy for major depressive disorder: speed and probability of remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19345072" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20008946" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21724669" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The search for improved antidepressant strategies: is bigger better?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20595426" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Issues for DSM-5: whither melancholia? The case for its classification as a distinct mood disorder.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
